Literature DB >> 12620236

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.

Thomas P J Garrett1, Neil M McKern, Meizhen Lou, Thomas C Elleman, Timothy E Adams, George O Lovrecz, Michael Kofler, Robert N Jorissen, Edouard C Nice, Antony W Burgess, Colin W Ward.   

Abstract

ErbB2 does not bind ligand, yet appears to be the major signaling partner for other ErbB receptors by forming heteromeric complexes with ErbB1, ErbB3, or ErbB4. The crystal structure of residues 1-509 of ErbB2 at 2.5 A resolution reveals an activated conformation similar to that of the EGFR when complexed with ligand and very different from that seen in the unactivated forms of ErbB3 or EGFR. The structure explains the inability of ErbB2 to bind known ligands and suggests why ErbB2 fails to form homodimers. Together, the data suggest a model in which ErbB2 is already in the activated conformation and ready to interact with other ligand-activated ErbB receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620236     DOI: 10.1016/s1097-2765(03)00048-0

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  204 in total

Review 1.  Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling.

Authors:  Joyce A Schroeder; Leslie F Jackson; David C Lee; Todd D Camenisch
Journal:  J Mol Med (Berl)       Date:  2003-06-25       Impact factor: 4.599

Review 2.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

3.  Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis.

Authors:  Peter Nagy; Jeroen Claus; Thomas M Jovin; Donna J Arndt-Jovin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-02       Impact factor: 11.205

4.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

5.  The tethering arm of the EGF receptor is required for negative cooperativity and signal transduction.

Authors:  Sangeeta Adak; Diana DeAndrade; Linda J Pike
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

Review 6.  EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?

Authors:  Shailender Singh Kanwar; Jyoti Nautiyal; Adhip P N Majumdar
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

7.  Dynamic transition states of ErbB1 phosphorylation predicted by spatial stochastic modeling.

Authors:  Meghan McCabe Pryor; Shalini T Low-Nam; Adám M Halász; Diane S Lidke; Bridget S Wilson; Jeremy S Edwards
Journal:  Biophys J       Date:  2013-09-17       Impact factor: 4.033

8.  Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface.

Authors:  Jessica P Dawson; Mitchell B Berger; Chun-Chi Lin; Joseph Schlessinger; Mark A Lemmon; Kathryn M Ferguson
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.

Authors:  Motoko Takahashi; Yoshihiro Hasegawa; Yoshitaka Ikeda; Yoshinao Wada; Michiko Tajiri; Shigeru Ariki; Rina Takamiya; Chiaki Nishitani; Motoko Araki; Yoshiki Yamaguchi; Naoyuki Taniguchi; Yoshio Kuroki
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

Review 10.  Muc4/MUC4 functions and regulation in cancer.

Authors:  Kermit L Carraway; George Theodoropoulos; Goldi A Kozloski; Coralie A Carothers Carraway
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.